Skip to content
Phanes Therapeutics, Inc
  • Careers
  • Contact Us
  • Home
  • About Us
    • Leadership Team
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Pipeline
  • Technology
  • Our Science
  • Partners & Collaborators
  • News
  • Careers
  • Contact Us

News

Home > News
    •  
    •  
    •  
    •  

News

Dec 14

2017

WuXi Biologics and Phanes announce strategic partnership

Shanghai and San Diego, Dec. 14, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering...
Read More
« Previous 1 … 4 5 6

Technology Platforms

Phanes' three technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties.
PACbody®: Build native IgG-like bispecific antibodies.
SPECpair®: Build bispecific antibodies with enhanced manufacturability.
ATACCbody®: Build bispecific antibodies with modulated activities.

Read More about Technology
  • About Us
  • Leadership Team
  • Scientific Advisory Board
  • Clinical Advisory Board
  • Therapeutic Areas
  • Phanes Therapeutics
  • Pipeline
  • Technology
  • Partners & Collaborators
  • News
  • Careers
  • Contact Us
  • Sitemap
© Phanes Therapeutics, Inc. — All Rights Reserved
Website by Axxiem